Targeted degradation of NDUFS1 by agrimol B promotes mitochondrial ROS accumulation and cytotoxic autophagy arrest in hepatocellular carcinoma
In conclusion, our study uncovers the anticancer mechanism of agrimol B in HCC involving the regulation of oxidative stress and autophagy, and suggests agrimol B as a potential therapeutic drug for HCC treatment.PMID:38697493 | DOI:10.1016/j.freeradbiomed.2024.04.242 (Source: Free Radical Biology and Medicine)
Source: Free Radical Biology and Medicine - May 2, 2024 Category: Biology Authors: Lixia Dong Li Luo Zihao Wang Shan Lian Mao Wang Xingyun Wu Jiawu Fan Yan Zeng Sijia Li Sinan Lv Yurong Yang Rong Chen Enhao Shen Wenyong Yang Changlong Li Kui Wang Source Type: research
Discovery of potent and novel dual NAMPT/BRD4 inhibitors for efficient treatment of hepatocellular carcinoma
Eur J Med Chem. 2024 Apr 26;271:116444. doi: 10.1016/j.ejmech.2024.116444. Online ahead of print.ABSTRACTThe NAPRT-induced increase in NAD+ levels was proposed as a mechanism contributing to hepatocellular carcinoma (HCC) resistance to NAMPT inhibitors. Thus, concurrently targeting NAMPT and NAPRT could be considered to overcome drug resistance. A BRD4 inhibitor downregulates the expression of NAPRT in HCC, and the combination of NAMPT inhibitors with BRD4 inhibitors simultaneously blocks NAD+ generation via salvage and the PH synthesis pathway. Moreover, the combination of the two agents significantly downregulated the ex...
Source: European Journal of Medicinal Chemistry - May 1, 2024 Category: Chemistry Authors: Chunjia Yin Shuting Jia Xiaojuan Yang Liqiang Wu Source Type: research
Multifaceted roles of lymphatic and blood endothelial cells in the tumor microenvironment of hepatocellular carcinoma: A comprehensive review
World J Hepatol. 2024 Apr 27;16(4):537-549. doi: 10.4254/wjh.v16.i4.537.ABSTRACTThe tumor microenvironment is a complex network of cells, extracellular matrix, and signaling molecules that plays a critical role in tumor progression and metastasis. Lymphatic and blood vessels are major routes for solid tumor metastasis and essential parts of tumor drainage conduits. However, recent studies have shown that lymphatic endothelial cells (LECs) and blood endothelial cells (BECs) also play multifaceted roles in the tumor microenvironment beyond their structural functions, particularly in hepatocellular carcinoma (HCC). This compr...
Source: World Journal of Hepatology - May 1, 2024 Category: Gastroenterology Authors: Jing-Jing Li Jia-Xi Mao Han-Xiang Zhong Yuan-Yu Zhao Fei Teng Xin-Yi Lu Li-Ye Zhu Yang Gao Hong Fu Wen-Yuan Guo Source Type: research
Erdafitinib and checkpoint inhibitors for first-line and second-line immunotherapy of hepatic, gastrointestinal, and urinary bladder carcinomas: Recent concept
World J Hepatol. 2024 Apr 27;16(4):490-493. doi: 10.4254/wjh.v16.i4.490.ABSTRACTCancer immunotherapy is administered for first-line, second-line, neoadjuvant, or adjuvant treatment of advanced, metastatic, and recurrent cancer in the liver, gastrointestinal tract, and genitourinary tract, and other solid tumors. Erdafitinib is a fibroblast growth factor receptor (FGFR) inhibitor, and it is an adenosine triphosphate competitive inhibitor of FGFR1, FGFR2, FGFR3, and FGFR4. Immune checkpoint inhibitors are monoclonal antibodies that block programmed cell death protein 1 (PD-1) and its ligand that exert intrinsic antitumor mec...
Source: World Journal of Hepatology - May 1, 2024 Category: Gastroenterology Authors: Mohamed Wishahi Source Type: research
Serum interleukin-10 and alpha-fetoprotein: A combined diagnostic approach for hepatocellular carcinoma in Egyptians with HCV
CONCLUSION: the reliability of AFP as a major HCC marker was poor. However, IL-10 levels are a novel biomarker for the degree of HCC inflammation, considering IL-10's potential role in HCV-HCC development. We suggest combining AFP with IL-10 to improve the diagnostic and prognostic value of HCC considerably. Future research on these biomarkers should prioritize their clinical validity, prognostic usefulness, and compatibility with other therapeutic approaches as immunotherapy.PMID:38692084 | DOI:10.1016/j.prp.2024.155327 (Source: Pathology, Research and Practice)
Source: Pathology, Research and Practice - May 1, 2024 Category: Pathology Authors: Mostafa A Sharafeldin Reda A Suef Adel A Mousa Dina H Ziadah Mohamed M S Farag Source Type: research
Long non-coding RNA LOXL1-AS1: a potential biomarker and therapeutic target in human malignant tumors
This article reviews the current understanding of the biological function and clinical significance of LOXL1-AS1 in human cancers. These findings suggest that LOXL1-AS1 may be both a reliable biomarker and a potential therapeutic target for cancers.PMID:38693424 | DOI:10.1007/s10238-024-01355-7 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 1, 2024 Category: Cancer & Oncology Authors: Xiao-Ping Fu Chun-Yan Ji Wen-Qian Tang Ting-Ting Yu Lei Luo Source Type: research
Long non-coding RNA LOXL1-AS1: a potential biomarker and therapeutic target in human malignant tumors
This article reviews the current understanding of the biological function and clinical significance of LOXL1-AS1 in human cancers. These findings suggest that LOXL1-AS1 may be both a reliable biomarker and a potential therapeutic target for cancers.PMID:38693424 | DOI:10.1007/s10238-024-01355-7 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - May 1, 2024 Category: Cancer & Oncology Authors: Xiao-Ping Fu Chun-Yan Ji Wen-Qian Tang Ting-Ting Yu Lei Luo Source Type: research
Long non-coding RNA LOXL1-AS1: a potential biomarker and therapeutic target in human malignant tumors
This article reviews the current understanding of the biological function and clinical significance of LOXL1-AS1 in human cancers. These findings suggest that LOXL1-AS1 may be both a reliable biomarker and a potential therapeutic target for cancers.PMID:38693424 | DOI:10.1007/s10238-024-01355-7 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - May 1, 2024 Category: Cancer & Oncology Authors: Xiao-Ping Fu Chun-Yan Ji Wen-Qian Tang Ting-Ting Yu Lei Luo Source Type: research
Multifunctional and stimuli-responsive liposomes in hepatocellular carcinoma diagnosis and therapy
Transl Oncol. 2024 Apr 30;45:101975. doi: 10.1016/j.tranon.2024.101975. Online ahead of print.ABSTRACTHepatocellular carcinoma (HCC) is the most prevalent type of liver cancer, mainly occurring in Asian countries with an increased incidence rate globally. Currently, several kinds of therapies have been deployed for HCC therapy including surgical resection, chemotherapy, radiotherapy and immunotherapy. However, this tumor is still incurable, requiring novel strategies for its treatment. The nanomedicine has provided the new insights regarding the treatment of cancer that liposomes as lipid-based nanoparticles, have been wid...
Source: Translational Oncology - May 1, 2024 Category: Cancer & Oncology Authors: Seyedeh Setareh Samaei Mahshid Daryab Sarah Gholami Aryan Rezaee Navid Fatehi Romina Roshannia Saeed Hashemi Nazanin Javani Parham Rahmanian Reza Amani-Beni Mohammad Arad Zandieh Noushin Nabavi Mohsen Rashidi Neda Malgard Mehrdad Hashemi Afshin Taheriazam Source Type: research
Discovery of potent and novel dual NAMPT/BRD4 inhibitors for efficient treatment of hepatocellular carcinoma
Eur J Med Chem. 2024 Apr 26;271:116444. doi: 10.1016/j.ejmech.2024.116444. Online ahead of print.ABSTRACTThe NAPRT-induced increase in NAD+ levels was proposed as a mechanism contributing to hepatocellular carcinoma (HCC) resistance to NAMPT inhibitors. Thus, concurrently targeting NAMPT and NAPRT could be considered to overcome drug resistance. A BRD4 inhibitor downregulates the expression of NAPRT in HCC, and the combination of NAMPT inhibitors with BRD4 inhibitors simultaneously blocks NAD+ generation via salvage and the PH synthesis pathway. Moreover, the combination of the two agents significantly downregulated the ex...
Source: European Journal of Medicinal Chemistry - May 1, 2024 Category: Chemistry Authors: Chunjia Yin Shuting Jia Xiaojuan Yang Liqiang Wu Source Type: research
Multifaceted roles of lymphatic and blood endothelial cells in the tumor microenvironment of hepatocellular carcinoma: A comprehensive review
World J Hepatol. 2024 Apr 27;16(4):537-549. doi: 10.4254/wjh.v16.i4.537.ABSTRACTThe tumor microenvironment is a complex network of cells, extracellular matrix, and signaling molecules that plays a critical role in tumor progression and metastasis. Lymphatic and blood vessels are major routes for solid tumor metastasis and essential parts of tumor drainage conduits. However, recent studies have shown that lymphatic endothelial cells (LECs) and blood endothelial cells (BECs) also play multifaceted roles in the tumor microenvironment beyond their structural functions, particularly in hepatocellular carcinoma (HCC). This compr...
Source: World Journal of Hepatology - May 1, 2024 Category: Gastroenterology Authors: Jing-Jing Li Jia-Xi Mao Han-Xiang Zhong Yuan-Yu Zhao Fei Teng Xin-Yi Lu Li-Ye Zhu Yang Gao Hong Fu Wen-Yuan Guo Source Type: research
Erdafitinib and checkpoint inhibitors for first-line and second-line immunotherapy of hepatic, gastrointestinal, and urinary bladder carcinomas: Recent concept
World J Hepatol. 2024 Apr 27;16(4):490-493. doi: 10.4254/wjh.v16.i4.490.ABSTRACTCancer immunotherapy is administered for first-line, second-line, neoadjuvant, or adjuvant treatment of advanced, metastatic, and recurrent cancer in the liver, gastrointestinal tract, and genitourinary tract, and other solid tumors. Erdafitinib is a fibroblast growth factor receptor (FGFR) inhibitor, and it is an adenosine triphosphate competitive inhibitor of FGFR1, FGFR2, FGFR3, and FGFR4. Immune checkpoint inhibitors are monoclonal antibodies that block programmed cell death protein 1 (PD-1) and its ligand that exert intrinsic antitumor mec...
Source: World Journal of Hepatology - May 1, 2024 Category: Gastroenterology Authors: Mohamed Wishahi Source Type: research
Serum interleukin-10 and alpha-fetoprotein: A combined diagnostic approach for hepatocellular carcinoma in Egyptians with HCV
CONCLUSION: the reliability of AFP as a major HCC marker was poor. However, IL-10 levels are a novel biomarker for the degree of HCC inflammation, considering IL-10's potential role in HCV-HCC development. We suggest combining AFP with IL-10 to improve the diagnostic and prognostic value of HCC considerably. Future research on these biomarkers should prioritize their clinical validity, prognostic usefulness, and compatibility with other therapeutic approaches as immunotherapy.PMID:38692084 | DOI:10.1016/j.prp.2024.155327 (Source: Pathology, Research and Practice)
Source: Pathology, Research and Practice - May 1, 2024 Category: Pathology Authors: Mostafa A Sharafeldin Reda A Suef Adel A Mousa Dina H Ziadah Mohamed M S Farag Source Type: research
Long non-coding RNA LOXL1-AS1: a potential biomarker and therapeutic target in human malignant tumors
This article reviews the current understanding of the biological function and clinical significance of LOXL1-AS1 in human cancers. These findings suggest that LOXL1-AS1 may be both a reliable biomarker and a potential therapeutic target for cancers.PMID:38693424 | DOI:10.1007/s10238-024-01355-7 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - May 1, 2024 Category: Cancer & Oncology Authors: Xiao-Ping Fu Chun-Yan Ji Wen-Qian Tang Ting-Ting Yu Lei Luo Source Type: research
Long non-coding RNA LOXL1-AS1: a potential biomarker and therapeutic target in human malignant tumors
This article reviews the current understanding of the biological function and clinical significance of LOXL1-AS1 in human cancers. These findings suggest that LOXL1-AS1 may be both a reliable biomarker and a potential therapeutic target for cancers.PMID:38693424 | DOI:10.1007/s10238-024-01355-7 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - May 1, 2024 Category: Cancer & Oncology Authors: Xiao-Ping Fu Chun-Yan Ji Wen-Qian Tang Ting-Ting Yu Lei Luo Source Type: research
